Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X Mult Scler. 2016 Jun 28. PMID: 27354019. Abstract CommentRecommendBookmarkWatch